Development of investigational antibody MEDI2452 for reversal of antiplatelet effects of ticagrelor
Biospace Inc.
A pre-clinical development program is evaluating the ability of MEDI2452 to rapidly and specifically reverse the antiplatelet effects of ticagrelor in emergency situations that cause major bleeding, such as surgery.
British Medical Journal
In patients with STEMI undergoing primary PCI, unfractionated heparin plus GpIIb/IIIa inhibitor (GPI) and LMWH plus GPI were most efficacious in terms of avoiding major adverse cardiovascular events in the short-term; bivalirudin was associated with the lowest bleeding risk.
Platelet Transfusion: A Clinical Practice Guideline From the AABB
Annals of Internal Medicine
These US guidelines provide pragmatic recommendations on the appropriate use of platelet transfusion (prophylactic and therapeutic) in adults, based on the best available published evidence.
Vitamin K for Patients with High International Normalized Ratios (INRs): Safety
Canadian Agency for Drugs and Technologies in Health
A limited literature search identified one non-randomised study which found that withholding warfarin or giving vitamin K treatment to patients on oral anticoagulants who have an INR >9 did not effectively reduce the INR within 24 hours.
European Medicines Agency
The PRAC is recommending further examination of the available evidence for Kogenate Bayer/Helixate NexGen, as new evidence has shown it may be associated with a higher risk of inhibitor (antibody) development than other FVIII products in treatment-naïve haemophilia patients.
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
